Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC CLINICAL ONCOLOGY
Citação
JOURNAL OF GLOBAL ONCOLOGY, v.4, 2017
Resumo
Purpose Extensive-stage small-cell lung cancer (esSCLC) is an incurable disease and represents a therapeutic challenge because of its poor prognosis. Studies in prophylactic cranial irradiation (PCI) in esSCLC have shown a decreased incidence of symptomatic brain metastases in patients who respond to systemic chemotherapy. However, its effect on overall survival is debatable. We evaluated the benefit of PCI in patients with esSCLC in terms of overall survival, progression-free survival, incidence of brain metastases, recurrence rate, and exposure to postrecurrence therapies. Materials and Methods We retrospectively reviewed electronic charts from patients diagnosed with esSCLC from 2008 to 2014 at our institution. All patients had negative baseline brain imaging before chemotherapy and PCI and received at least 4 cycles of platinum-based chemotherapy in the first-line setting without progressive disease on follow-up. PCI was performed at the discretion of the treating physician. Analyses were based on descriptive statistics. Survival curves were calculated by Kaplan-Meier method. Results Among 46 eligible patients, 16 (35%) received PCI and 30 (65%) did not. Compared with no PCI, PCI led to improved progression-free survival (median, 10.32 v 7.66 months; hazard ratio, 0.4521; 95% CI, 0.2481 to 0.8237; P < .001) and overall survival (median, 20.94 v 11.05 months; hazard ratio, 0.2655; 95% CI, 0.1420 to 0.4964; P < .001) as well as lower incidence of brain metastases (19% v 53%; P = .0273) and higher exposure to second-line chemotherapy (87% v 57%; P = .0479). Conclusion Careful patient selection for PCI can improve not only brain metastases control and higher second-line chemotherapy exposure but also patient survival. (c) 2017 by American Society of Clinical Oncology
Palavras-chave
Referências
- Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954
- Auperin A, 1999, NEW ENGL J MED, V341, P476, DOI 10.1056/NEJM199908123410703
- Gregor A, 1997, EUR J CANCER, V33, P1752, DOI 10.1016/S0959-8049(97)00135-4
- HERSKOVIC AM, 1986, INT J RADIAT ONCOL, V12, P427, DOI 10.1016/0360-3016(86)90363-9
- JOHNSON BE, 1990, J CLIN ONCOL, V8, P48, DOI 10.1200/JCO.1990.8.1.48
- Kato T, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8005
- Khuntia D, 2006, J CLIN ONCOL, V24, P1295, DOI 10.1200/JCO.2005.04.6185
- Le Pechoux C, 2009, LANCET ONCOL, V10, P467, DOI 10.1016/S1470-2045(09)70101-9
- Mehta MP, 2006, J CLIN ONCOL, V24, P3524, DOI 10.1200/JCO.2006.06.9096
- Micke P, 2002, LUNG CANCER, V37, P271, DOI 10.1016/S0169-5002(02)00072-7
- National Comprehensive Cancer Network, NCCN GUID SMALL CELL
- PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302
- Seute T, 2008, CANCER, V112, P1827, DOI 10.1002/cncr.23361
- SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3
- Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780
- Slotman BJ, 2009, J CLIN ONCOL, V27, P78, DOI 10.1200/JCO.2008.17.0746
- Stahel RA, 1989, LUNG CANCER, V5, P119, DOI 10.1016/0169-5002(89)90156-6
- Takahashi T, 2017, LANCET ONCOL, V18, P663, DOI 10.1016/S1470-2045(17)30230-9
- van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7
- Wolfson AH, 2011, INT J RADIAT ONCOL, V81, P77, DOI 10.1016/j.ijrobp.2010.05.013
- Wolfson AH, 2001, AM J CLIN ONCOL-CANC, V24, P290, DOI 10.1097/00000421-200106000-00017